[ad_1]
The new vaccine against coronavirus (COVID-19), jointly developed by the pharmaceutical company AstraZeneca and the University of Oxford, has shown 70% efficiency. This is demonstrated by the results of large-scale studies, according to world news agencies.
In a press release, the British-Swedish multinational pharmaceutical company AstraZeneca said its testing on more than 20,000 volunteers has shown that the vaccine prevents people from developing symptoms in an average of 70% of cases.
The news follows recent reports that vaccines developed by Pfizer and Moderna have been shown to be around 95% effective.
Pfizer has requested permission from the United States for the emergency use of a coronavirus vaccine
This marks the beginning of a process
The latest candidate vaccine is injected in two doses at least one month apart, similar to other vaccines.
The test found that Vaccine efficacy varies by dose size, an unexpected finding.
When patients received two full doses, the vaccine was found to be 62% effective.
However, when patients received half the dose in the first vaccination, followed by the full dose in the second vaccination, the efficacy increased to 90%.
Taking both methods together, this has resulted in an average efficiency of 70%, AstraZeneca said.
Oxford vaccine creates immunity to Covid-19 in adults
The vaccine is better administered by older people than by younger people.
It is not clear why different doses have different degrees of efficacy.
According to the BBC, although less effective overall, the Oxford / AstraZeneca vaccine is cheaper to produce and easier to store than vaccines from US pharmaceutical giants Pfizer and Moderna.
The technology was developed by the University of Oxford and its company Vaccitech. AstraZeneca signed a contract with the university in April 2020 for further development, mass production and potential distribution of the vaccine.
Development of the vaccine failed in September when trials were suspended after an “unexplained illness” in a trial participant from the UK.
Updated
Pfizer / BioNTech vaccine is 95% effective, they want a marketing authorization
In a few days, Pfizer will send documents to the Food and Drug Administration.
Clinical trials resumed when regulators in the United States, Great Britain, Brazil, South Africa and Japan confirmed that it is safe to do so.
Since then, trial results have been promising, and second-stage trial results published in The Lancet in November show that the vaccine elicited an immune response and was safe for all generations.
The next step is for the vaccine to get the green light from regulators around the world.
The European Medicines Agency has already started to evaluate the laboratory data of the vaccine, with the aim of speeding up the procedure.
Fauci was “extremely impressed” by Moderna’s COVID-19 vaccine
“This is really a spectacular result.”
[ad_2]
